Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: A post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients

Bays, Harold; Maccubbin, Darbie; Meehan, Alan G.; Kuznetsova, Olga M.; Mitchel, Yale; Paolini, John F.

doi:10.1016/j.clinthera.2009.01.010

Cited by 32 publications

(38 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In 1613 patients with primary hypercholesterolaemia or mixed dyslipidaemia, extended-release niacin (ERN) use was associated with signifi cant reductions in systolic ( p < 0.05) and diastolic ( p < 0.001) blood pressure [ 21 ]. Similar results were shown when ERN/laropiprant was added to statin treatment in 68 normotensive and hypertensive dyslipidaemic patients who were treated with a conventional statin dose and had not achieved lipid targets [ 22 ].…”

Section: Effi Cacy Of Niacinsupporting

confidence: 74%

Statins and Niacin: The End of Residual Risk Therapy?

Agouridis

Mikhailidis

2015

Combination Therapy in Dyslipidemia

View full text Add to dashboard Cite

Section: Effi Cacy Of Niacinsupporting

confidence: 74%

Statins and Niacin: The End of Residual Risk Therapy?

Agouridis

Mikhailidis

2015

Combination Therapy in Dyslipidemia

View full text Add to dashboard Cite

“…Based on previous studies we estimated that ER-NA/laropiprant would result in a 3% reduction of BP [15], while switching to rosuvastatin would not alter BP since patients were already receiving a statin. Power analysis revealed that a sample size of 30 patients per group would give a 99% power to detect differences between groups at an α level lower than 0.05.…”

Section: Methodsmentioning

confidence: 99%

“…Recently, the European Medicine Agency approved a fixed combination of extended release (ER) NA with laropiprant (a prostaglandin D2 receptor antagonist) which reduces NA-induced flushing without altering the beneficial effects of NA on lipid profile or BP [13–15]. …”

Section: Introductionmentioning

confidence: 99%

Add-on-Statin Extended Release Nicotinic Acid/Laropiprant but Not the Switch to High-Dose Rosuvastatin Lowers Blood Pressure: An Open-Label Randomized Study

Kei

Elisaf

Moutzouri

et al. 2011

International Journal of Hypertension

View full text Add to dashboard Cite

Introduction. Nicotinic acid (NA) and statins have been associated with reductions in blood pressure (BP). Patients and Methods. We recruited 68 normotensive and hypertensive dyslipidemic patients who were treated with a conventional statin dose and had not achieved lipid targets. Patients were randomized to switch to high-dose rosuvastatin (40 mg/day) or to add-on current statin treatment with extended release (ER) NA/laropiprant (1000/20 mg/day for the first 4 weeks followed by 2000/40 mg/day for the next 8 weeks) for 3 months. Results. Switching to rosuvastatin 40 mg/day was not associated with significant BP alterations. In contrast, the addition of ER-NA/laropiprant to current statin treatment resulted in a 7% reduction of systolic BP (from 134 ± 12 to 125 ± 10 mmHg, P < .001 versus baseline and P = .01 versus rosuvastatin group) and a 5% reduction of diastolic BP (from 81 ± 9 to 77 ± 6 mmHg, P = .009 versus baseline and P = .01 versus rosuvastatin group). These reductions were significant only in the subgroup of hypertensives and were independent of the hypolipidemic effects of ER-NA/laropiprant. Conclusions. Contrary to the switch to high-dose rosuvastatin, the addition of ER-NA/laropiprant to statin treatment was associated with significant reductions in both systolic and diastolic BP.

show abstract

“…Another study investigated the effect of extended release niacin in conjunction with a prostaglandin D 2 receptor subtype 1 antagonist (laropiprant) which found a modest, but statistically signifi cant lowering of both SBP and DBP by about 2 to 3 mmHg each, regardless of whether laropiprant was used or not ( 1 ). This suggests that the hypotensive effect of niacin is not mediated by prostaglandin D 2 alone.…”

Section: Discussionmentioning

confidence: 93%

“…The vasodilation is caused by a release of prostaglandin D 2 and prostaglandin E 2 from Langerhans skin cells and macrophages, which stimulate receptors found on the vascular smooth muscle cells in dermal arterioles ( 1,7 ). This effect has infl uenced a few investigations into the possibility that niacin has a sustained blood pressure lowering action.…”

Section: Discussionmentioning

confidence: 98%

Reduced G Tolerance Associated With Supplement Use

Barker¹

2011

aviat space environ med

View full text Add to dashboard Cite

The case presented here details a Naval Aviator who experienced reduced G tolerance over two successive flights with a temporal relationship of starting a new supplement. Two components of the supplement, coenzyme Q10 and niacin, are highlighted here for their hemodynamic effects. After stopping the supplement the aviator regained his normal G tolerance and had no further issues in flight. There are several factors that can reduce G tolerance and supplement use has to be considered here because of the potential for altering the normal physiological response to increased G force. Our discussion reviews the physiological effects of increased G force, the spectrum of signs of decompensation under the stress of G force, and the potential effects this supplement had on the normal physiological response to increased G force, thus reducing the aviator's G tolerance.

show abstract

Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: A post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients

Cited by 32 publications

References 11 publications

Statins and Niacin: The End of Residual Risk Therapy?

Statins and Niacin: The End of Residual Risk Therapy?

Add-on-Statin Extended Release Nicotinic Acid/Laropiprant but Not the Switch to High-Dose Rosuvastatin Lowers Blood Pressure: An Open-Label Randomized Study

Reduced G Tolerance Associated With Supplement Use

Contact Info

Product

Resources

About